NTLA Today - Jul 10: Intellia's Wild Ride

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

NTLA Today - Jul 10: Intellia's Wild Ride

無料で聴く

ポッドキャストの詳細を見る

Hey there! It’s Joey, your friendly neighborhood investor, here to break down what just went down with Intellia, or NTLA for short. Today was a rough one – the stock got smoked, down about 7% by the end of the day. Ouch!

So, what happened? Well, Intellia had a wild ride lately, with a big surge just yesterday. People were super hyped because they were about to get the first-ever Phase 3 readout for their gene-editing therapy. But today? That excitement took a nosedive. The volume was pretty high, though, so clearly, a lot of folks were trading it, but the mood shifted fast.

Now, why did it drop? A couple of reasons. Some analysts are saying the stock looks pricey when you consider sales versus returns. Like, yeah, it might seem rich on paper, but the actual performance isn’t matching the hype. Plus, there’s chatter that it could be around 37% below what it should be worth based on its gene-editing prospects. That kind of uncertainty can make investors hit the sell button real quick.

And here’s something worth keeping an eye on: Wedbush just raised their price target for NTLA to $17. That’s a little glimmer of hope in an otherwise cloudy day.

So, to wrap it up: NTLA had a rough day after a big high yesterday. Analysts are a bit skeptical about its valuation, which definitely rattled some nerves. Just remember, I’m here to share info and keep it fun, but this isn’t financial advice. Always do your own homework! Catch you later!

まだレビューはありません